GLP-1 (glucagon-like peptide-1) receptor agonists (GLP-1 RAs) are among the most pharmacologically consequential drug class introduced in the past two decades. Their actions extend far beyond glucose lowering to encompass substantial and durable weight loss, clinically proven reduction of major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease, renal protection, and emerging evidence in heart failure with preserved ejection fraction. Understanding the breadth of GLP-1 receptor biology is essential to understanding why these agents produce such diverse and clinically important effects across multiple organ systems.
The GLP-1 receptor (GLP-1R) is a Class B GPCR (G protein-coupled receptor, class B being the secretin receptor family) that couples primarily to Gs proteins, activating adenylyl cyclase and generating cAMP (cyclic adenosine monophosphate) as the primary second messenger. In pancreatic beta cells, cAMP activates PKA (protein kinase A) and the cAMP-binding exchange protein EPAC2 (exchange protein directly activated by cAMP 2, also called RAPGEF4). PKA phosphorylates multiple targets including voltage-gated potassium channels (prolonging the action potential), L-type calcium channels (enhancing calcium influx), and proteins of the exocytotic machinery (increasing vesicle fusion probability). EPAC2 activates Rap1, which further amplifies calcium signaling and insulin granule mobilization. The net effect in the presence of elevated glucose is an amplification of GSIS (glucose-stimulated insulin secretion) approximately 3 to 5-fold above the basal glucose-stimulated rate. This amplification is strictly glucose-dependent: at fasting glucose levels, GLP-1R-mediated cAMP generation does not produce sufficient calcium influx to trigger exocytosis, explaining the absence of hypoglycemia at therapeutic GLP-1 RA (receptor agonist) doses.1
GLP-1R expression extends well beyond pancreatic beta cells and encompasses a distribution that maps precisely onto the pleiotropic clinical effects of pharmacological GLP-1 agonism. In pancreatic alpha cells, GLP-1R activation suppresses glucagon secretion in a glucose-dependent manner, making a substantial contribution to postprandial glucose lowering; this glucagon suppression is maintained by GLP-1 RAs even in the alpha cell-centric hyperglucagonemia characteristic of T2DM (type 2 diabetes mellitus). In the stomach, GLP-1R activation on vagal afferent neurons and gastric smooth muscle slows gastric emptying, reducing the rate of postprandial glucose delivery to the duodenum and blunting postprandial excursions independent of the insulin-secretory effect. In the hypothalamus, GLP-1R activation in the arcuate nucleus and nucleus tractus solitarius (NTS) suppresses NPY (neuropeptide Y)/AgRP (agouti-related peptide) neurons, activates POMC (pro-opiomelanocortin) neurons, and reduces orexigenic signaling, producing a durable reduction in food intake that is the primary driver of weight loss with GLP-1 RAs. Peripheral gut signals, vagal afferent activation, and direct brain penetration all contribute to this central appetite-suppressing effect.2
The cardiovascular and renal GLP-1R actions are mechanistically distinct from the glycemic effects and are believed to underlie the cardiovascular outcome benefits documented in multiple large randomized trials. In the heart, GLP-1R is expressed on cardiomyocytes, endothelial cells, and macrophages. GLP-1R activation reduces oxidative stress, improves mitochondrial biogenesis, activates cardioprotective PI3K (phosphoinositide 3-kinase)/Akt signaling, and inhibits NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells)-mediated inflammatory gene transcription. In the vasculature, GLP-1R activation on endothelial cells increases NO (nitric oxide) production via eNOS (endothelial nitric oxide synthase) phosphorylation, promotes vasodilation, reduces VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) expression, and attenuates monocyte adhesion. In the kidney, GLP-1R activation reduces proximal tubular sodium reabsorption via inhibition of the NHE3 (sodium-hydrogen exchanger 3) transporter, producing natriuresis and reducing intraglomerular pressure; anti-inflammatory effects in podocytes and mesangial cells further contribute to renoprotection. These non-glycemic organ-level effects occur at GLP-1R concentrations achieved by pharmacological agonism but not by the low physiological GLP-1 concentrations extended by DPP-4 (dipeptidyl peptidase-4) inhibitors, providing a mechanistic explanation for why GLP-1 RAs but not DPP-4 inhibitors produce cardiovascular and renal outcome benefits.3
GLP-1 (glucagon-like peptide-1) receptor agonists are peptide molecules that cannot be administered orally in conventional formulations due to rapid gastrointestinal proteolytic degradation and negligible passive absorption across the intestinal epithelium. The evolution from twice-daily short-acting exenatide to once-weekly long-acting agents and finally to oral semaglutide represents a pharmacokinetic engineering trajectory driven by the desire to minimize injection burden and achieve stable systemic exposure. Each structural modification strategy has distinct pharmacokinetic and pharmacodynamic consequences.
The first structural class is exendin-4-based agents, peptides derived from the Gila monster salivary protein exendin-4 that shares 53 percent sequence homology with human GLP-1 but is resistant to DPP-4 (dipeptidyl peptidase-4) cleavage due to the Gly2 substitution at its N-terminus. Exenatide (twice-daily formulation) has a plasma half-life of approximately 2 to 4 hours, requiring twice-daily subcutaneous injection; it produces primarily postprandial glucose lowering and modest weight loss. Exenatide extended-release (once weekly, suspension microparticle formulation) achieves sustained release over 7 days, producing more stable plasma levels and greater HbA1c reductions than twice-daily exenatide. Because exenatide is a non-human peptide sequence, immunogenicity is a consideration: approximately 30 to 40 percent of patients develop anti-exenatide antibodies, which in a small proportion are neutralizing and attenuate efficacy. Neither exenatide formulation is renally cleared as an intact peptide (proteolytic degradation predominates), but renal impairment slows clearance of degradation products; exenatide is generally avoided when eGFR (estimated glomerular filtration rate) falls below 30 mL/min/1.73m2.11
The second structural class is human GLP-1-based agents, peptides with sequence homology to endogenous GLP-1 but engineered for extended half-life. Liraglutide has a single amino acid substitution (Lys34Arg) and an eighteen-carbon (C18) fatty acid attached via a glutamic acid linker to Lys26, enabling reversible albumin binding that slows renal clearance and proteolytic degradation, extending the half-life to approximately 13 hours and enabling once-daily subcutaneous dosing. Semaglutide (weekly injection or daily oral) has a more potent fatty acid modification (C18 diacid spacer) that produces tighter albumin binding, a half-life of approximately 165 to 184 hours (approximately 7 days), and greater receptor potency than liraglutide at equivalent molar concentrations.4 Dulaglutide achieves weekly dosing through fusion of two modified GLP-1 peptides to an IgG4 (immunoglobulin G4) Fc (fragment crystallizable) fragment, producing a large molecule (approximately 59 kDa) that resists proteolysis and clears slowly via reticuloendothelial catabolism. Albiglutide, which was withdrawn from the US market for commercial reasons in 2018 but remains approved in some regions, achieves weekly dosing through fusion to human albumin.11
Oral semaglutide (Rybelsus) represents a pharmacokinetic breakthrough for the GLP-1 RA (receptor agonist) class, achieved by co-formulating semaglutide with SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate), an absorption enhancer that transiently permeabilizes the gastric mucosa and increases local pH, enabling transcellular absorption of semaglutide across the gastric epithelium before duodenal proteolytic degradation can occur. The absolute bioavailability of oral semaglutide is approximately 1 to 2 percent, requiring a starting dose of 3 mg daily and titration to 7 mg and potentially 14 mg to achieve glucose lowering comparable to the injectable 0.5 to 1.0 mg weekly dose. Oral semaglutide must be taken on an empty stomach with up to 120 mL of water, with at least 30 minutes before eating, drinking (except water), or taking other medications, to avoid impairing SNAC-mediated absorption. Despite the low absolute bioavailability, the PIONEER (Peptide InnOvatioN for Early diabEtes tReatment) trials demonstrated that oral semaglutide 14 mg daily produces HbA1c reductions and weight loss comparable to injectable semaglutide 0.5 mg weekly, establishing the first oral GLP-1 RA with clinically meaningful glycemic and weight effects.515
Pharmacodynamic differences between short-acting and long-acting GLP-1 RAs are clinically significant. Short-acting agents (exenatide twice daily, liraglutide to some degree) slow gastric emptying most prominently during the prandial period, producing predominant postprandial glucose lowering but also the most pronounced GI (gastrointestinal) adverse effects around the time of injection. Long-acting agents (once-weekly semaglutide, dulaglutide, exenatide extended-release) produce more stable continuous GLP-1R (GLP-1 receptor) stimulation, resulting in tachyphylaxis of the gastric emptying effect (gastric emptying normalizes over time despite continued receptor activation), shifting the glucose-lowering mechanism toward fasting glucose suppression via sustained glucagon inhibition. The weight loss efficacy correlates with peak receptor occupancy and the degree of central GLP-1R activation, which is greatest with the highest-potency agents; semaglutide produces substantially greater weight loss (approximately 6 to 15 percent body weight reduction at various doses) than liraglutide (approximately 5 to 8 percent) or dulaglutide (approximately 2 to 4 percent), reflecting its higher receptor affinity and more sustained central GLP-1R engagement.6
The cardiovascular outcome trial program for GLP-1 (glucagon-like peptide-1) RAs has produced some of the most practice-changing evidence in endocrinology, establishing that several agents in this class reduce MACE (major adverse cardiovascular events: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in patients with established ASCVD (atherosclerotic cardiovascular disease) or high cardiovascular risk. This evidence is not a class effect uniformly shared by all agents and does not appear to operate through glycemic lowering alone.
The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial randomized 9,340 patients with T2DM (type 2 diabetes mellitus) and established cardiovascular disease or multiple cardiovascular risk factors to liraglutide 1.8 mg daily versus placebo, all receiving standard care. After a median follow-up of 3.8 years, MACE occurred in 13.0 percent of the liraglutide group versus 14.9 percent of placebo (HR (hazard ratio) 0.87; 95% CI (confidence interval) 0.78–0.97; p=0.01 for superiority), driven predominantly by reductions in cardiovascular death and non-fatal stroke. Renal outcomes were also improved: liraglutide reduced the composite of new-onset macroalbuminuria, doubling of serum creatinine, end-stage renal disease, or renal death by 22 percent.7
The SUSTAIN-6 (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) trial randomized 3,297 patients with T2DM and established or high cardiovascular risk to once-weekly semaglutide (0.5 mg or 1.0 mg) versus placebo. MACE occurred in 6.6 percent with semaglutide versus 8.9 percent with placebo (HR 0.74; 95% CI 0.58–0.95; p=0.02), a result driven substantially by non-fatal stroke reduction (39 percent relative risk reduction). A post-hoc observation noted increased non-fatal MI (myocardial infarction), though not statistically significant. The SUSTAIN-6 trial was a cardiovascular safety trial rather than a superiority trial and was not powered to characterize individual endpoint components. The subsequent FLOW (Semaglutide Treatment Effect in People with Obesity and CKD) trial demonstrated that once-weekly semaglutide significantly reduced the composite renal outcome (sustained 50 percent reduction in eGFR, kidney failure, renal death, or cardiovascular death) by 24 percent in patients with T2DM and chronic kidney disease, providing the first dedicated renal outcome evidence for a GLP-1 RA (receptor agonist).8
Dulaglutide in the REWIND (Researching Cardiovascular Events with a Weekly INcretin in Diabetes) trial enrolled 9,901 patients with T2DM and either established cardiovascular disease (31 percent) or multiple cardiovascular risk factors (69 percent), making it the first GLP-1 RA CVOT (cardiovascular outcome trial) with a majority primary prevention population. Dulaglutide reduced MACE by 12 percent (HR 0.88; 95% CI 0.79–0.99; p=0.026), driven by non-fatal stroke reduction, establishing cardiovascular benefit even in a predominantly lower-risk population.9 Exenatide extended-release in the EXSCEL (Exenatide Study of Cardiovascular Event Lowering) trial showed numerical MACE reduction that did not reach statistical significance (HR 0.91; p=0.06), highlighting that cardiovascular benefit is not a fully uniform class effect and may differ by agent, patient population, and trial design.14 Albiglutide in the Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (HARMONY OUTCOMES) trial demonstrated significant MACE reduction (HR 0.78; p=0.0006) in a high-risk cardiovascular population, reinforcing the benefit particularly in secondary prevention patients.13
The mechanism of GLP-1 RA cardiovascular benefit is believed to be primarily anti-atherosclerotic and anti-inflammatory, operating through the direct vascular and cardiac GLP-1R (GLP-1 receptor) effects described in Section 1, rather than through glycemic lowering. Evidence supporting this interpretation includes: the early divergence of cardiovascular event curves within months (before meaningful HbA1c differences emerge), the preservation of benefit after adjustment for glycemic changes, the predominantly stroke-driven benefit consistent with endothelial and plaque-stabilizing mechanisms, and the absence of heart failure hospitalization reduction (which would be expected if the benefit were driven by cardiac unloading through glycosuric weight loss, as seen with SGLT-2 (sodium-glucose cotransporter-2) inhibitors). The differential cardiovascular benefit between agents correlates imperfectly with glycemic potency, supporting a direct pharmacological mechanism rather than a glucose-mediated pathway. Meta-analyses of completed GLP-1 RA CVOTs confirm significant reductions in MACE (approximately 14 percent), cardiovascular death (approximately 12 percent), and stroke (approximately 16 percent) across the class, with no excess heart failure hospitalization signal.13
The adverse effect profile of GLP-1 (glucagon-like peptide-1) RAs is dominated by gastrointestinal effects that are mechanistically driven by the pharmacological actions of the class and are therefore predictable, dose-dependent, and largely manageable with appropriate titration strategies. Serious safety signals have emerged from the development program but require careful contextual interpretation to guide appropriate clinical use.
Nausea, vomiting, diarrhea, and abdominal discomfort are the dominant adverse effects of GLP-1 RAs, affecting 30 to 50 percent of patients during dose initiation and affecting 10 to 20 percent persistently at maintenance doses. These effects arise from the same mechanisms that produce the therapeutic effects: GLP-1R (GLP-1 receptor)-mediated slowing of gastric emptying (producing nausea and early satiety) and central area postrema activation (a circumventricular brain region involved in emesis regulation, accessible to circulating GLP-1 analogs). With once-weekly agents, GI (gastrointestinal) symptoms are typically most pronounced in the first 4 to 8 weeks of treatment and diminish significantly as gastric GLP-1R tachyphylaxis develops; with short-acting agents, symptoms recur transiently around each injection. The standard management strategy is low-dose initiation with gradual monthly titration: liraglutide 0.6 mg once daily for 1 week, then 1.2 mg for 1 week, then 1.8 mg (glycemic dose); semaglutide 0.25 mg once weekly for 4 weeks, then 0.5 mg, then 1.0 mg. Patients should avoid high-fat, high-calorie meals during dose escalation and eat smaller portions. Persistent intolerable nausea after adequate titration is a legitimate indication to switch to a different agent within the class (tolerability varies among agents) or to discontinue.10
The medullary thyroid carcinoma (MTC) concern arises from rodent carcinogenicity studies in which all GLP-1 RAs tested produced dose-dependent C-cell hyperplasia and MTC in rats and mice, attributed to GLP-1R stimulation of calcitonin secretion from thyroid C cells. The clinical relevance of this finding is uncertain: rodent thyroid C cells have substantially higher GLP-1R expression density than human C cells, and human MTC does not express GLP-1R in most pathological specimens. Post-marketing pharmacovigilance has not identified a clear excess MTC signal in humans, and population-based studies with liraglutide (the longest-exposure data) have not confirmed elevated MTC incidence. Nonetheless, the FDA mandated a black-box warning, and all GLP-1 RAs are contraindicated in patients with a personal or family history of MTC or in patients with MEN2 (multiple endocrine neoplasia type 2) syndrome, in which MTC risk is genetically determined and calcitonin secretion is already elevated. Routine calcitonin monitoring during GLP-1 RA (receptor agonist) therapy is not recommended in the absence of specific risk factors.11
Retinopathy worsening was a notable finding in the SUSTAIN-6 (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) trial: patients randomized to semaglutide had a significantly higher rate of diabetic retinopathy complications (HR 1.76; p=0.02) compared with placebo. This is believed to represent a paradoxical worsening associated with rapid HbA1c reduction, analogous to the early retinopathy deterioration observed with intensive insulin therapy in the DCCT (Diabetes Control and Complications Trial) — a recognized phenomenon where acute glycemic correction can transiently destabilize ischemic retinal vasculature. This finding was not pre-specified as a primary endpoint in SUSTAIN-6, was not seen in the LEADER (Liraglutide Effect and Action in Diabetes) trial with liraglutide, and is not observed with slower glycemic correction. The current clinical implication is to avoid rapid HbA1c reduction in patients with pre-existing moderate to severe diabetic retinopathy, regardless of the agent used, and to schedule ophthalmological evaluation before initiating GLP-1 RA therapy in patients with known retinopathy.8
Pancreatitis remains a class precaution for all incretin-based therapies, including GLP-1 RAs. As discussed in Diab-03, the dedicated CVOTs have not confirmed a statistically significant increase in acute pancreatitis across the incretin classes, though a pharmacovigilance signal exists. GLP-1 RAs should be discontinued if acute pancreatitis is confirmed. They are used with caution in patients with a history of pancreatitis, though ADA (American Diabetes Association) guidance does not classify prior pancreatitis as an absolute contraindication in patients without ongoing pancreatic disease. An additional safety signal is gallbladder disease: GLP-1 RAs reduce gallbladder motility through CNS (central nervous system) and direct GLP-1R effects, increasing biliary lithogenicity. Meta-analyses show an approximately 25 to 40 percent increased risk of cholelithiasis and cholecystitis with GLP-1 RAs, particularly at higher doses and with greater weight loss. Patients should be counseled about biliary symptoms during treatment and biliary ultrasound obtained when biliary symptoms arise.11
GLP-1 RAs do not cause hypoglycemia as monotherapy or when combined with metformin, TZDs, DPP-4 inhibitors, SGLT-2 inhibitors, or AGIs, because their insulin-secretory effect is strictly glucose-dependent. However, when GLP-1 RAs are combined with sulfonylureas or insulin, the enhanced insulin secretion (GLP-1 RA) plus fixed or semi-fixed insulin delivery (sulfonylurea or insulin) can produce hypoglycemia, particularly if the patient's food intake decreases due to appetite suppression from the GLP-1 RA. Standard practice when initiating a GLP-1 RA in a patient on a sulfonylurea is to reduce the sulfonylurea dose by 25 to 50 percent at initiation; when combined with basal insulin, insulin dose reduction of 10 to 20 percent is typically appropriate, with subsequent titration guided by fasting glucose monitoring.
GLP-1 (glucagon-like peptide-1) receptor agonists have ascended to the highest priority tier in T2DM (type 2 diabetes mellitus) pharmacotherapy guidelines for patients with established ASCVD (atherosclerotic cardiovascular disease) or high cardiovascular risk, based on the convergence of cardiovascular outcome trial evidence, substantial weight loss effect, favorable hypoglycemia profile, and emerging renal outcome data. The prescribing framework requires integration of cardiovascular risk stratification, patient-specific weight goals, tolerability profile, and cost-access considerations.
The 2023 ADA/EASD (American Diabetes Association/European Association for the Study of Diabetes) consensus guidelines place GLP-1 RAs as the preferred second agent (after metformin) for patients with T2DM and established ASCVD, regardless of baseline HbA1c, and as a preferred option (alongside SGLT-2 (sodium-glucose cotransporter-2) inhibitors) when substantial weight loss is the primary treatment goal. In patients without established ASCVD but with high cardiovascular risk, multiple cardiovascular risk factors, or obesity, GLP-1 RAs remain strongly preferred over sulfonylureas, TZDs, or AGIs when cost permits. The 2024 ADA (American Diabetes Association) Standards of Care explicitly list agents with proven cardiovascular benefit (liraglutide, semaglutide subcutaneous, dulaglutide, albiglutide) as the preferred GLP-1 RAs in patients with established ASCVD, while noting that evidence of cardiovascular benefit is the key criterion for agent selection within the class rather than HbA1c potency.12
Agent selection within the GLP-1 RA (receptor agonist) class is guided by four primary considerations: cardiovascular risk, weight loss priority, injection frequency preference, and cost-access. For patients with established ASCVD prioritizing cardiovascular risk reduction, semaglutide subcutaneous (SUSTAIN-6 superiority), liraglutide (LEADER superiority), and dulaglutide (REWIND superiority) all have outcome trial evidence for cardiovascular benefit; semaglutide is preferred when both cardiovascular risk reduction and maximal weight loss are goals, given its superior efficacy on both endpoints. For patients prioritizing weight loss, semaglutide (subcutaneous or oral, higher doses) or high-dose liraglutide (Saxenda 3 mg, approved for weight management but not diabetes) are highest-efficacy options. For patients preferring less frequent injections, once-weekly agents (semaglutide, dulaglutide, exenatide extended-release) are standard. For patients unable to afford injectable GLP-1 RAs, oral semaglutide, where available, provides the only non-injectable option within the class. All agents are administered subcutaneously in the abdomen, thigh, or upper arm; rotation prevents lipohypertrophy. Storage requirements vary: most require refrigeration prior to first use but can be maintained at room temperature after opening for limited periods per manufacturer guidance.12
In patients with CKD (chronic kidney disease), GLP-1 RAs are generally safe without dose adjustment across most stages of renal impairment, representing an important advantage over metformin (restricted below eGFR 30) and sulfonylureas (metabolite accumulation). Liraglutide and semaglutide have been studied in CKD populations in the context of their CVOTs (cardiovascular outcome trials) and the dedicated FLOW (Semaglutide Treatment Effect in People with Obesity and CKD) trial, and neither requires renal dose adjustment through CKD stages 1 to 4. Exenatide is the exception: it is renally cleared to a greater degree and is avoided when eGFR falls below 30 mL/min/1.73m2. In patients with eGFR below 15 or on dialysis, the safety database for all GLP-1 RAs is limited; liraglutide and semaglutide are used in practice with close monitoring in this population, though formal approval in dialysis patients is absent for most agents. The FLOW trial evidence specifically supports semaglutide for renal protection in patients with CKD and T2DM, making it the preferred GLP-1 RA in that setting when renal endpoints are a primary concern.11
The role of GLP-1 RAs in T1DM (type 1 diabetes mellitus) is investigational in most regulatory jurisdictions, with no current FDA approval for this indication. Mechanistically, several features of GLP-1 RA pharmacology are potentially beneficial in T1DM: glucagon suppression (which contributes to postprandial glucose excursions and DKA risk), appetite suppression and weight loss (addressing insulin-associated weight gain), and slowed gastric emptying (improving post-meal glucose predictability). Small randomized trials have demonstrated modest HbA1c reduction and weight loss with GLP-1 RAs as add-on to insulin in T1DM, but with increased DKA (diabetic ketoacidosis) risk reported in some studies, particularly with SGLT-2 inhibitor combinations. The ADA currently notes that GLP-1 RAs may be considered in adults with T1DM and BMI (body mass index) of 30 or greater as adjunct to insulin, with close monitoring, but this remains an off-label use requiring individual benefit-risk assessment.12
GLP-1 RA initiation failures are almost entirely attributable to inadequate tolerability management. Key principles: (1) Start at the lowest recommended dose regardless of glycemic urgency. (2) Titrate no faster than the labeled schedule; many patients benefit from slower-than-labeled titration. (3) Counsel patients that nausea typically peaks in weeks 2 to 4 and diminishes substantially by weeks 6 to 8. (4) Recommend small, low-fat meals during dose escalation; avoid eating to the point of fullness. (5) Inject once-weekly agents consistently on the same day of the week at any time of day. (6) For oral semaglutide: empty stomach, 120 mL water only, 30-minute pre-meal wait — non-negotiable for absorption. (7) Pre-emptively reduce sulfonylurea or insulin doses to prevent hypoglycemia from the amplified insulin effect plus reduced food intake. (8) If a patient stops due to GI intolerance, resume at the prior tolerated dose rather than restarting the titration from scratch.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
doi:10.1016/j.cmet.2018.03.001Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
doi:10.1053/j.gastro.2007.03.054Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536.
doi:10.1016/S2213-8587(15)00482-9Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380.
doi:10.1021/acs.jmedchem.5b00726Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Oral semaglutide: a review of the first oral glucagon-like peptide-1 receptor agonist. Diabetes Technol Ther. 2020;22(1):10–18.
doi:10.1089/dia.2019.0185Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–536.
doi:10.1111/dom.12849Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
doi:10.1056/NEJMoa1603827Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
doi:10.1056/NEJMoa1607141Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
doi:10.1016/S0140-6736(19)31149-3Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250.
doi:10.1016/S0140-6736(08)61206-4Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Mol Metab. 2021;46:101102.
doi:10.1016/j.molmet.2020.101102American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
doi:10.2337/dc24-SINTKristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785.
doi:10.1016/S2213-8587(19)30249-9Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
doi:10.1056/NEJMoa1509225Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
doi:10.1056/NEJMoa1901118